Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines
2020 Dyslipidemia CPG
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually, lower his risk for cardiovascular disease.
Philippine Lipid and Atherosclerosis Society / Philippine Heart Association / Philippine Society of Endocrinology, Diabetes and Metabolism. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines. https://www.philheart.org/index.php/guidelines/142-dyslipidemia-guidelines. Accessed February 1, 2020.
GRADE your evidence and improve your guideline in development in health care. https://gradepro.org.
Breda Eubank, Mohtadi NG, Lafve MR, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56. https://www.ncbi.nlm.nih.gov/pubmed/27206853. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875724. https://doi.org/10.1186/s12874-016-0165-8.
Pijlman A, Huijgen R, Verhagen SN, et al. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209(1):189–94. https://www.ncbi.nlm.nih.gov/pubmed/19818960. https://doi.org/10.1016/j.atherosclerosis.2009.09.014.
Expert Panel on Integrated Guidelines for cardiovascular health and risk reduction in children and adolescents, National Heart, Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011;128 (Suppl 5):S213-56. https://www.ncbi.nlm.nih.gov/pubmed/22084329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536582. https://doi.org/10.1542/peds.2009-2107C.
Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. J Clin Endocrinol Metab. 2014;99(9):3093-102. https://www.ncbi.nlm.nih.gov/pubmed/24848708. https://doi.org/10.1210/jc.2013-3860.
Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet. 2010; 376(9753):1658-69. https://www.ncbi.nlm.nih.gov/pubmed/21067805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988223. https://doi.org/10.1016/S0140-6736(10)60310-8.
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16. https://www.ncbi.nlm.nih.gov/pubmed/15337732. https://doi.org/10.1001/jama.292.11.1307.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. https://www.ncbi.nlm.nih.gov/pubmed/15755765. https://doi.org/10.1056/NEJMoa050461.
Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA.2005;294(19):2437-45. https://www.ncbi.nlm.nih.gov/pubmed/16287954. https://doi.org/10.1001/jama.294.19.2437.
Copyright (c) 2021 Lourdes Ella Gonzalez-Santos, Raymond Oliva, Cecilia Jimeno, Eddieson Gonzales, Maria Margarita Balabagno, Deborah Ona, Jude Erric Cinco, Agnes Baston, Imelda Caoile, Mia Fojas, Ruzenette Felicitas Hernandezj, Ma. Cristina Macrohon-Valdez, Ma. Theresa Rosqueta, Feliz Eduardo Punzalan, Elmer Jasper Llanes
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to email@example.com or firstname.lastname@example.org.
A written agreement shall be emailed to the requester should permission be granted.